OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Completed · Phase 2 · Has a placebo group

Conditions studied: Depressive Disorder, Major

In brief

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.

Key facts

Study ID
NCT02116361
Run by
Allergan
People needed
258
Starts
2014-04-22
Expected to finish
2016-12-22
Last updated by the study team
2017-12-19

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.